What are Complement C5a receptor antagonist drugs?

Complement C5a receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting C5a receptor (C5aR)). 0 are currently marketed, with 4 more in clinical development.

Complement C5a receptor antagonist

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all Complement C5a receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting C5a receptor (C5aR), C5aR1 (C5a receptor 1).

Targets

C5a receptor (C5aR) · C5aR1 (C5a receptor 1)

Phase 3 pipeline (3)

LJPC-501 · La Jolla Pharmaceutical Company · Immunology / Inflammation
LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.
KK8398 · Kyowa Kirin Co., Ltd. · Immunology
KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.
MP-513 · Tanabe Pharma Corporation · Immunology
MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.

Phase 2 pipeline (1)

ASP5541 · Astellas Pharma Global Development, Inc. · Immunology
ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.